Welcome to our dedicated page for TuHURA Biosciences SEC filings (Ticker: HURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TuHURA Biosciences, Inc. (NASDAQ: HURA) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. TuHURA is a Phase 3 immuno-oncology company developing IFx-2.0, a lead innate immune agonist for advanced or metastatic Merkel cell carcinoma, the VISTA inhibiting monoclonal antibody TBS-2025 for NPM1-mutated relapsed/refractory acute myeloid leukemia, and Delta Opioid Receptor-based antibody drug conjugate programs aimed at overcoming resistance to cancer immunotherapy.
Through this page, users can review TuHURA’s current and historical filings, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports that disclose material events. Recent 8-K filings describe, among other items, the completion of the acquisition of Kineta, Inc., the reverse merger with Kintara Therapeutics, Inc., the initiation of the Phase 3 IFx-2.0 trial under a Special Protocol Assessment agreement with the FDA, the establishment of an at-the-market offering facility, a secured bridge loan agreement, and the effectiveness of a shelf registration statement on Form S-3.
Investors can also use this page to locate registration statements such as Form S-1 and Form S-3 related to public and resale offerings of TuHURA’s common stock, including PIPE financings and warrant exercises. Where applicable, pro forma financial information filed as exhibits to 8-Ks provides combined financial data reflecting TuHURA’s merger transactions. Insider ownership changes and executive equity activity, when reported on Form 4 and related forms, can be monitored alongside these core filings.
Stock Titan enhances this raw filing data with AI-powered summaries that highlight key points from lengthy documents, helping users understand how TuHURA’s clinical development plans, risk factor updates, financing arrangements, and merger-related disclosures appear in its official SEC reports. Real-time updates from EDGAR ensure that new TuHURA filings, including 10-Ks, 10-Qs, 8-Ks, registration statements, and ownership reports, are quickly available for review and comparison.
TuHURA Biosciences reported fourth quarter and full year 2025 results and highlighted progress across its immuno-oncology pipeline. The company is running a Phase 3 accelerated approval trial of IFx-2.0 in advanced or metastatic Merkel Cell Carcinoma and a Phase 1b/2a study in MCC of unknown primary, while advancing VISTA inhibitor TBS-2025 and an ADC program toward key 2026–2027 milestones.
Cash and cash equivalents were $3.6 million at December 31, 2025, with an additional $7.5 million received in Q1 2026 from a 2025 registered direct offering. Research and development expenses rose to $20.5 million in 2025 from $13.3 million in 2024, and general and administrative expenses increased to $7.6 million from $3.9 million, reflecting expanded operations and the Kineta acquisition. Net cash outflows from operating activities were $27.7 million in 2025, partly offset by $19.9 million of net cash inflows from financing activities. TuHURA reported approximately 52.9 million shares outstanding as of December 31, 2025.
TuHURA Biosciences, Inc. files its annual report describing a late‑stage immuno‑oncology pipeline focused on overcoming primary and acquired resistance to cancer immunotherapies. The company is a Phase 3 clinical-stage developer centered on its IFx innate immune agonist platform.
Lead candidate IFx‑2.0 is in a single randomized, placebo‑controlled Phase 3 trial as adjunctive therapy to Keytruda in first‑line advanced or metastatic Merkel cell carcinoma under an FDA Special Protocol Assessment and accelerated approval pathway. TuHURA also acquired Kineta and its VISTA‑inhibiting antibody TBS‑2025 for planned Phase 1b/2 studies in relapsed/refractory mutNPM1 acute myeloid leukemia, and is advancing Delta Opioid Receptor–targeted bi‑functional, bi‑specific ADCs against myeloid‑derived suppressor cells.
The report outlines the company’s history of reverse mergers, licensing deals with Moffitt Cancer Center and West Virginia University for DOR technology, a broad patent estate extending into the 2040s, and an organization of 22 employees based primarily in Tampa, Florida.
Tendler Craig reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
Ng George K reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
TuHURA Biosciences, Inc. reported that Highbridge Capital Management, LLC has become a significant holder of its common stock through warrants. Highbridge reports beneficial ownership of 6,060,608 shares of TuHURA common stock, all issuable upon exercise of warrants held by funds and accounts it advises.
This position represents 9.1% of TuHURA’s common stock, calculated using 60,720,508 shares outstanding as of December 10, 2025, after a recently completed offering and assuming warrant exercise. Highbridge has sole voting and dispositive power over these warrant shares and is filing as an investment adviser.
The filing states the securities were acquired and are held in the ordinary course of business, not with the purpose or effect of changing or influencing control of TuHURA. Highbridge Tactical Credit Master Fund, L.P., one of the advised funds, has rights over more than 5% of the outstanding shares.
MANUSO JAMES S J reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
List Alan reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
Hoffman Robert E. reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
TuHURA Biosciences, Inc. received a notice from Nasdaq that its common stock no longer meets the minimum bid price requirement because the consolidated closing bid has been below $1.00 per share for 35 consecutive business days as of January 28, 2026. The stock is not being immediately delisted, and the company has a 180-day grace period, until July 28, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days. If it still fails to comply, TuHURA may be eligible for a second 180-day period, potentially including measures such as a reverse stock split, and could also request a hearing to delay any suspension or delisting. The company states that the notice does not affect its business, operations, or SEC reporting, but it cautions that there is no assurance it will regain or maintain Nasdaq listing compliance.
TuHURA Biosciences, Inc. reported an insider equity award for its Chief Financial Officer, Dan Dearborn. On January 6, 2026, he was granted 273,696 options (right to buy common stock) with an exercise price of $0.73 per share, expiring on January 6, 2036. The options were acquired at no cost and are held directly. According to the footnote, this is a supplemental option grant to an option grant previously made in December 2025, and one-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.